SignatureFD’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History

SignatureFD’s Portfolio NGM Stock Details NGM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-5,451	Closed	-$22.2K	–	3392
2023 Q1	$22.2K	Buy	5,451 +5,135	+1,625%	+$23.7K	﹤0.01%	1810
2022 Q4	$1.59K	Sell	316 -31	-9%	-$194	﹤0.01%	2873
2022 Q3	$5K	Buy	347 +206	+146%	+$3.12K	﹤0.01%	2485
2022 Q2	$2K	Buy	141 +69	+96%	+$956	﹤0.01%	2836
2022 Q1	$1K	Buy	+72	New	+$1.12K	﹤0.01%	3092
2021 Q2	–	Sell	-24	Closed	-$1K	–	3094
2021 Q1	$1K	Buy	+24	New	+$672	﹤0.01%	2715

Other funds holding NGM

Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

SignatureFD's NGM Position: Q2 2023 in Review

SignatureFD sold out of NGM Biopharmaceuticals, Inc. Common Stock (NGM) in Q2 2023, closing a stake of 5,451 shares — an estimated $22.2K sold.

SignatureFD first reported a position in NGM in Q1 2021 and held it in 6 quarters. The position peaked at $22.2K in Q1 2023. 106 funds tracked by Wall St. Rank hold NGM as of Q2 2023.

SignatureFD reported no remaining NGM Biopharmaceuticals, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
SignatureFD sold 5,451 NGM Biopharmaceuticals, Inc. Common Stock shares in Q2 2023, an estimated $22.2K.
SignatureFD first reported a position in NGM Biopharmaceuticals, Inc. Common Stock in Q1 2021 and held it in 6 quarters.
SignatureFD's NGM Biopharmaceuticals, Inc. Common Stock position peaked at $22.2K in Q1 2023.
106 funds tracked by Wall St. Rank held NGM Biopharmaceuticals, Inc. Common Stock as of Q2 2023.

Based on SignatureFD's 13F filing for Q2 2023, filed 1 Aug 2023.